Difference between revisions of "Team:Tongji China"

Line 15: Line 15:
 
                         <div class="content">
 
                         <div class="content">
 
                         <center><img src="https://static.igem.org/mediawiki/2018/c/cc/T--Tongji_China--picture-Homepage-1_LOGO.png" width="100%" style="margin-bottom: 15%;padding-top: 10%;"></center>
 
                         <center><img src="https://static.igem.org/mediawiki/2018/c/cc/T--Tongji_China--picture-Homepage-1_LOGO.png" width="100%" style="margin-bottom: 15%;padding-top: 10%;"></center>
<div style="height: auto;margin-bottom: 20%;">
+
<div style="height: 100%;margin-bottom: 20%;">
 
<img src="https://static.igem.org/mediawiki/2018/5/5c/T--Tongji_China--picture-Home_page-1.png" width="50%;" style="float: left;">
 
<img src="https://static.igem.org/mediawiki/2018/5/5c/T--Tongji_China--picture-Home_page-1.png" width="50%;" style="float: left;">
  

Revision as of 10:22, 14 October 2018

Home
Welcome to
Tongji_China
We focus our attention
on the cancer therapy
and T3SS to create
a new method to present
the promising individual
cancer antigen ——“Neoantigen”
We use the bioinformatic
method to filter our item
antigens and use the T3SS
in P.A. to present these
antigens to the T cells
through orally intake.
We filter the antigens of
interest. Then we conduct
various experiments to
prove that our system can
work efficiently and safely.
To improve the Integrity and
feasibility of our project, we
consult many people for
advices.
We utilize the Wechat pushes
to popularize our project idea.
Each member in Tongji_China
contribute a great effect to
make our project better.
And also we appreciate the
collaboration with iGEMers
and iGEM teams.